Skip to main content

Table 1 Characteristics of 1390 SCZ patients with T2D (n = 536) and without T2D (n = 854)

From: Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study

Characteristics SCZ without T2D
n = 854 (61.44%)
SCZ with T2D
n = 536 (38.56%)
Corrected
p value****
Mean (SD)*
 Age (years) 45.83 (12.98) 57.07 (12.25) < 0.0001
 SCZ duration (years) 18.57 (11.69) 26.30 (11.61) < 0.0001
 BMI (kg/m2) 25.97 (4.54) 30.56 (6.75) < 0.0001
n (%)**
 Male 516 (60.42%) 310 (57.84%) 0.467
 Female 338 (39.58%) 226 (42.16%)
 Number of subjects who reported outdoor physical activity in last week 16 (1.87%) 4 (0.75%) 0.172
 Number of subjects who reported no outdoor physical activity in last week 838 (98.13%) 532 (99.25%)
Median (IQR)***
 Number of Hospitalizations 4.00 (3.00–7.00) 3.00 (2.00–6.00) < 0.0001
 Positive Symptoms 31.00 (27.00–36.00) 32.00 (27.00–37.00) 0.532
 Negative Symptoms 30.00 (26.50–34.00) 30.00 (25.00–34.00) 0.486
 General Psychopathology Scale 55.00 (48.00–64.00) 54.00 (47.00–64.00) 0.179
 PANSS total score 118.00 (105.00–130.50) 117.00 (103.00–131.00) 0.467
  1. SD: standard deviation; IQR: interquartile range
  2. *t-test, **x2 test, ***Wilcoxon Rank Sum test, ****Corrected p-value using Benjamini and Hochberg method for the comparison between SCZ patients with and without T2D